Catalonia has always been known for its dynamic nature and great capacity for growth, innovation and entrepreneurship. And this is precisely what stands out about the companies in the health and biomedicine sector today.  

Each year, CataloniaBio & HealthTech, with collaboration from EY, compiles the Study on investment in the Biomedical industry in Catalonia: Achievements and future challenges in order to reflect the main indicators and provide an analysis of business investment in the Catalan biomedical ecosystem to valorise and make it more attractive for investors, companies and international talent.

The presentation of the 2018 edition will be on 12 June at the Auditorium of the Cercle d'Economia in Barcelona, with Jaume Amat, president of CataloniaBio & HealthTech and CEO of Specipig, and Silvia Ondategui, managing partner of the EY Life Sciences division.

For CataloniaBio & HealthTech members and by invitation only. Please confirm attendance.

After the event, the digital version of the study will be available in the “Publications” section of this website. 

On Twitter #InversióCataloniaBioHT